Artificial Intelligence (AI) is no longer limited to just chatbots, image generation or data analysis; Its role in healthcare is increasing rapidly. Apart from detecting diseases and making medicines, AI has now taken a big step in the field of making vaccines as well. Scientists claim that they have created the world’s first AI-designed vaccine, which protects not just against a single virus, but against an entire family of viruses.
Researchers from Cambridge University, UK, have worked together with biotech company DIOSynVax on this new technology. He says that this vaccine can provide protection against the existing virus as well as future strains and potentially dangerous new viruses. This technology has completed an important phase of initial testing on humans; The vaccine was found safe in initial clinical trials and now it will be tested on a large scale on more than 200 people.
A new phase in the field of vaccine making
So far, most vaccines have been designed to target a specific virus or a specific strain. Although this strategy has saved millions of lives, viruses constantly mutate and change their form. This is why vaccines for diseases like flu and COVID-19 need to be updated from time to time. Researchers believe that the current approach keeps scientists in a constant race to fight the virus; By the time a new virus is identified, a vaccine is made, and it reaches people, the infection has often spread. According to Professor Jonathan Heaney of Cambridge University, the COVID-19 pandemic has shown that even though we can make vaccines faster, our thinking is still outdated. Their goal is to create a vaccine that can target the entire family of viruses.
How did AI create this vaccine?
For this project, scientists analyzed genomic data of coronavirus collected from around the world. This included data on past outbreaks, current infections and animal viruses that could infect humans in the future. AI and machine learning systems analyzed this genetic data to identify parts of the virus that remain largely the same over time. Scientists found so many essential elements for the survival of the virus that any mutation could have weakened the virus. Based on this analysis, researchers developed a unique “super-antigen”. Antigen is a component that prepares the body’s immune system to recognize a pathogen (disease-causing germ). Traditional vaccines typically target antigens of a single virus, but this new antigen was designed to take into account common features of several related coronaviruses. Scientists believe that a vaccine made in this way can remain effective even when there are major genetic changes in the virus.
What is Universal Sarbaccovirus Vaccine?
The vaccine used in trials on humans is called universal sarbaccovirus vaccine. Sarbacoviruses are a subgroup of the coronavirus family that includes SARS-CoV-2 (which is responsible for COVID-19), the virus that caused the 2003 SARS pandemic, and several coronaviruses found in bats. Instead of targeting a single virus, this vaccine focuses on the common biological characteristics of the entire group. This enables the body’s immune system to recognize and fight not just one but many related viruses.
What were the results of the initial human trials?
According to a study published in June, the main objective of the Phase 1 trial was to assess the safety of the vaccine. Healthy volunteers aged 18 to 50 years participated in this study. The vaccine was delivered as a DNA-based formulation using a special microfluidic jet system. This technology does not require traditional needles; Instead, a high-pressure jet of liquid delivers the vaccine into the skin. The trial found that the vaccine was safe and capable of generating immune responses against several types of coronaviruses. The special thing is that immune activity was seen not only against SARS-CoV-2 and SARS, but also against some coronaviruses spread by bats, which may pose a threat in the future. Although scientists acknowledge that the immune response is still in its early stages, the Phase 1 trial is aimed at assessing safety and initial efficacy; Its effectiveness will be assessed in more detail in subsequent larger trials.
How can this help prevent future pandemics?
Researchers believe that if the common characteristics of a virus family are identified in advance, a vaccine can be made even before the epidemic spreads. Surveillance programs around the world are currently collecting data on thousands of viruses found in humans and animals. By analyzing this data with the help of AI, scientists can predict potential threats and prepare preventive measures in advance. The purpose of this strategy is not just to respond to the pandemic, but to prepare for it.
Will this technology also work against bird flu and Ebola?
Researchers are now using the same platform for other dangerous viruses as well. The most prominent among these is bird flu (H5N1), which has affected birds, mammals and humans in many parts of the world. Scientists say that there are many strains of bird flu, some of which prove to be extremely fatal for humans; This AI-powered technology can help in creating a strong protective shield against such different strains. Additionally, the platform is also being tested against the Ebola virus family. Current vaccines are not equally effective against all types of Ebola virus; The aim of the researchers is to create a vaccine that can provide protection against the entire virus family.
Can this revolutionize healthcare?
Although this technology is still in its initial stages and is yet to be tested on a large scale, scientists consider it a major change in the field of vaccination. If future trials are successful, it may be possible to create vaccines that protect against an entire virus family, rather than just one disease. With this, the world will be able to be prepared in advance, and not rush to make a vaccine after the epidemic spreads. This new approach based on AI points towards a future of healthcare where humanity will be one step ahead of viruses instead of always being behind them.
